Sumatriptan provokes coronary artery spasm in patients with variant angina: Possible involvement of serotonin 1B receptor

International Journal of Cardiology

Volumn 114, Issue 2, 2007, Pages 188-194

  Shimizu, Masakatsu ^a   Hata, Katsuya ^a   Takaoka, Hideyuki ^a   Kanazawa, Kenji ^a   Shinke, Toshiro ^a   Matsumoto, Hidenari ^a   Watanabe, Satoshi ^a   Yoshikawa, Ryohei ^a   Masai, Hiroyuki ^a   Miyamoto, Yoshitomo ^a   Akita, Hozuka ^a   Yokoyama, Mitsuhiro ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Coronary artery spasm; Platelet aggregation; Serotonin; Sumatriptan; Variant angina

Indexed keywords

SEROTONIN 1B RECEPTOR; SUMATRIPTAN;

ADULT; AGED; ARTERY CONSTRICTION; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY SPASM; FEMALE; HUMAN; INTRACORONARY INFUSION; MALE; PRIORITY JOURNAL; PROVOCATION TEST; STATISTICAL SIGNIFICANCE; THROMBOCYTE ACTIVATION; VARIANT ANGINA PECTORIS;

ADULT; ANGINA PECTORIS, VARIANT; CORONARY VASOSPASM; CORONARY VESSELS; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTOR, SEROTONIN, 5-HT1B; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 33751214181     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.01.026     Document Type: Article

References (39)

1. Hillis L.D., and Braunwald E. Coronary-artery spasm. N Engl J Med 299 (1978) 695-702
2. Maseri A., Severi S., Nes M.D., et al. "Variant" angina: one aspect of a continuous spectrum of vasospastic myocardial ischemia. Pathogenetic mechanisms, estimated incidence and clinical and coronary arteriographic findings in 138 patients. Am J Cardiol 42 (1978) 1019-1035
3. Konidala S., and Gutterman D.D. Coronary vasospasm and the regulation of coronary blood flow. Prog Cardiovasc Dis 46 (2004) 349-373
4. Willerson J.T., Golino P., Eidt J., Campbell W.B., and Buja L.M. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation 80 (1989) 198-205
5. van den Berg E.K., Schmitz J.M., Benedict C.R., Malloy C.R., Willerson J.T., and Dehmer G.J. Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology. Circulation 79 (1989) 116-124
6. Rubanyl G.M., Frye R.L., Holmes Jr. D.R., and Vanhoutte P.M. Vasoconstrictor activity of coronary sinus plasma from patients with coronary artery disease. J Am Coll Cardiol 9 (1987) 1243-1249
7. Golino P., Piscione F., Willerson J.T., et al. Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med 324 (1991) 641-648
8. McFadden E.P., Clarke J.G., Davies G.J., Kaski J.C., Haider A.W., and Maseri A. Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N Engl J Med 324 (1991) 648-654
9. Kanazawa K., Suematsu M., Ishida T., et al. Disparity between serotonin- and acetylcholine-provoked coronary artery spasm. Clin Cardiol 20 (1997) 146-152
10. Kaumann A.J., Frenken M., Posival H., and Brown A.M. Variable participation of 5-HT1-like receptors and 5-HT2 receptors in serotonin-induced contraction of human isolated coronary arteries. 5-HT1-like receptors resemble cloned 5-HT1D beta receptors. Circulation 90 (1994) 1141-1153
11. Ishida T., Hirata K., Sakoda T., Kawashima S., Akita H., and Yokoyama M. Identification of mRNA for 5-HT1 and 5-HT2 receptor subtypes in human coronary arteries. Cardiovasc Res 41 (1999) 267-274
12. Ishida T., Hirata K., Sakoda T., et al. 5-HT1Dbeta receptor mediates the supersensitivity of isolated coronary artery to serotonin in variant angina. Chest 113 (1998) 243-244
13. De Caterina R., Carpeggiani C., and L'Abbate A. A double-blind, placebo-controlled study of ketanserin in patients with Prinzmetal's angina. Evidence against a role for serotonin in the genesis of coronary vasospasm. Circulation 69 (1984) 889-894
14. McFadden E.P., Bauters C., Lablanche J.M., et al. Effect of ketanserin on proximal and distal coronary constrictor responses to intracoronary infusion of serotonin in patients with stable angina, patients with variant angina, and control patients. Circulation 86 (1992) 187-195
15. Ozaki Y., Satoh K., Yatomi Y., Yamamoto T., Shirasawa Y., and Kume S. Detection of platelet aggregates with a particle counting method using light scattering. Anal Biochem 218 (1994) 284-294
16. Qi R., Ozaki Y., Satoh K., et al. Quantitative measurement of various 5-HT receptor antagonists on platelet activation induced by serotonin. Thromb Res 81 (1996) 43-54
17. Shimizu M., Kanazawa K., Matsuda Y., et al. Serotonin-2A receptor gene polymorphisms are associated with serotonin-induced platelet aggregation. Thromb Res 112 (2003) 137-142
18. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
19. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285 (2001) 2486-2497
20. Diagnosis and classification of diabetes mellitus. Diabetes Care 27 Suppl. 1 (2004) S5-S10
21. Guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Coronary Angiography). Circulation 76 (1987) 963A-977A
22. Palmer J., Feldman R., Mancini G.B., and Zimmerman M. Glyceryl trinitrate reversal of post-sumatriptan coronary artery narrowing. Lancet 345 (1995) 1366
23. Kaumann A.J., Parsons A.A., and Brown A.M. Human arterial constrictor serotonin receptors. Cardiovasc Res 27 (1993) 2094-2103
24. MaassenVanDenBrink A., Bax W.A., Ferrari M.D., Zijlstra F.J., Bos E., and Saxena P.R. Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane. Br J Pharmacol 119 (1996) 855-862
25. MaassenVanDenBrink A., Reekers M., Bax W.A., Ferrari M.D., and Saxena P.R. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 98 (1998) 25-30
26. Mueller L., Gallagher R.M., and Ciervo C.A. Vasospasm-induced myocardial infarction with sumatriptan. Headache 36 (1996) 329-331
27. MacIntyre P.D., Bhargava B., Hogg K.J., Gemmill J.D., and Hillis W.S. Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 87 (1993) 401-405
28. Connor H.E., Feniuk W., and Humphrey P.P. 5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activation. Eur J Pharmacol 161 (1989) 91-94
29. Ottervanger J.P., Paalman H.J., Boxma G.L., and Stricker B.H. Transmural myocardial infarction with sumatriptan. Lancet 341 (1993) 861-862
30. Curtin T., Brooks A.P., and Roberts J.A. Cardiorespiratory distress after sumatriptan given by injection. BMJ 305 (1992) 713-714 [author reply 4]
31. MaassenVanDenBrink A., van den Broek R.W., de Vries R., Bogers A.J., Avezaat C.J., and Saxena P.R. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 55 (2000) 1524-1530
32. Macintyre P.D., Bhargava B., Hogg K.J., Gemmill J.D., and Hillis W.S. The effect of i.v. sumatriptan, a selective 5-HT1-receptor agonist on central haemodynamics and the coronary circulation. Br J Clin Pharmacol 34 (1992) 541-546
33. McFadden E.P., Bauters C., Lablanche J.M., Quandalle P., Leroy F., and Bertrand M.E. Response of human coronary arteries to serotonin after injury by coronary angioplasty. Circulation 88 (1993) 2076-2085
34. van den Broek R.W., Bhalla P., VanDenBrink A.M., de Vries R., Sharma H.S., and Saxena P.R. Characterization of sumatriptan-induced contractions in human isolated blood vessels using selective 5-HT(1B) and 5-HT(1D) receptor antagonists and in situ hybridization. Cephalalgia 22 (2002) 83-93
35. Nilsson T., Longmore J., Shaw D., et al. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol 372 (1999) 49-56
36. Egashira K., Inou T., Yamada A., Hirooka Y., and Takeshita A. Preserved endothelium-dependent vasodilation at the vasospastic site in patients with variant angina. J Clin Invest 89 (1992) 1047-1052
37. Miyata K., Shimokawa H., Higo T., et al. Sarpogrelate, a selective 5-HT2A serotonergic receptor antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model. J Cardiovasc Pharmacol 35 (2000) 294-301
38. Ishida T., Kawashima S., Hirata K., and Yokoyama M. Nitric oxide is produced via 5-HT1B and 5-HT2B receptor activation in human coronary artery endothelial cells. Kobe J Med Sci 44 (1998) 51-63
39. Kuga T., Egashira K., Mohri M., et al. Bradykinin-induced vasodilation is impaired at the atherosclerotic site but is preserved at the spastic site of human coronary arteries in vivo. Circulation 92 (1995) 183-189